The effects of cyclosporin a on eicosanoid excretion in patients with rheumatoid arthritis

Authors:
  • AMA. Maier
    A. Maier
Open Access
Publisher website
Google Scholar
Abstract
Alterations in renal eicosanoid levels have been postulated as a factor in cyclosporin A (CSA) nephro‐toxicity. The effects of CSA on renal eicosanoid excretion in rheumatoid arthritis were studied over a 24‐week period, during which treatment with nonsteroidal anti‐inflammatory drugs was discontinued. The initial dosage of CSA was 4 mg/kg/day; at week 24, the mean dosage of CSA was 3.9 mg/kg/day. At week 24, the mean (±SD) serum creatinine level (1.04 ± 0.24 mg/dl) was 32% above the baseline value; renal blood flow had decreased by 21% (P < 0.03) and the glomerular filtration rate had decreased by 16%. There was a significant increase (P < 0.03) in the 2,3‐dinor thromboxane B2 level at week 2, but there was no significant change in the levels of the other eicosanoids. This study demonstrates that after CSA treatment, there is a selective increase in a thromboxane metabolite that parallels an increase in renal vascular resistance, even in the absence of nonsteroidal antiinflammatory drugs, and with unimpaired formation of other vasodilator eicosanoids.

This publication has 13 references indexed in Scilit: